1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: Interferon

Competitor Analysis: Interferon

  • April 2013
  • -
  • La Merie Publishing
  • -
  • 89 pages

Product description

The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural interferon alpha, beta, gamma, lambda and of other subtypes for treatment of hepatitis B and C, other infectious diseases, cancer and multiple sclerosis, respectively. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products and projects. Competitor projects are listed in a tabular format providing information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Interferon
Table of Contents

1. Interferon alpha, beta and other sub-types

a) INTERFERON alpha
Interferon alpha sales 2012 of branded products in regulated markets
1st generation Interferon alpha-2a in regulated markets
1st generation Interferon alpha-2a in non-regulated markets
Next generation Interferon alpha-2a in regulated markets
Next generation Interferon alpha-2a in non-regulated markets and biosimilars
1st generation Interferon alpha-2b in regulated markets
1st generation Interferon alpha-2b in non-regulated markets and biosimilars
Next generation Interferon alpha-2b in regulated markets
Next generation Interferon alpha-2b in non-regulated markets and biosimilars
Other Interferon alpha sub-types
Interferon alpha with not specified sub-type - 1/2
Purified natural human interferon alpha

b) Consensus INTERFERONs

c) INTERFERON beta
Interferon beta sales 2012 of branded products in regulated markets
1st generation Interferon beta-1a in regulated markets
1st generation Interferon beta-1a in non-regulated markets and biosimilars
1st generation Interferon beta-1b in regulated markets
1st generation Interferon beta-1b in non-regulated markets and biosimilars
1st generation Interferon beta with not disclosed sub-type
Next generation Interferon beta in regulated markets
Purified natural human interferon beta

d) INTERFERON gamma

e) Other INTERFERONs

2. Corporate Interferon Product Portfolios and RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global protein labeling market is expected to reach USD 1,894.5 million by 2020 from USD 1,089.5 million in 2015, at a CAGR of 11.7% from 2015 to 2020. On the basis of products, the protein labeling ...

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Global Pea Protein Market

December 2016 $ 4250

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.